- Augurex to present a poster and share a second accepted abstract at EULAR 2025, taking place June 11–14 in Barcelona.
- New findings highlight the value of 14-3-3eta autoantibodies in improving early detection of axSpA, including in HLA-B27–negative patients.
Vancouver, Canada – June 4, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced its participation in the European Congress of Rheumatology (EULAR) 2025, taking place June 11–14 in Barcelona, Spain.
EULAR is one of the world’s most prominent rheumatology congresses, bringing together clinicians, researchers, and industry leaders to accelerate advances in the care of autoimmune and inflammatory diseases.
At this year’s meeting, Augurex will showcase the latest data focused on the role of 14-3-3eta autoantibodies in the diagnosis and monitoring of axial spondyloarthritis (axSpA)—a chronic condition for which delayed diagnosis remains a significant clinical challenge.
Accepted Abstracts:
- Poster Presentation (POS-717) | Validation of Anti-14-3-3η (eta) Multiplex Laboratory Developed Test (LDT) for the Diagnosis of Axial Spondyloarthritis (axSpA)
○ Presenting Author: Dr. Anthony Marotta
○ Date and Time: Wednesday, June 11 at 3:30 PM
- Accepted Abstract (1601) | The 14-3-3η autoantibody assay combines with CRP and HLA-B27 to maximize the identification of patients with axial spondyloarthritis including in HLA-B27 negative patients; A validation study.
These presentations build on growing clinical evidence that supports the use of 14-3-3eta autoantibodies as a first-in-class biomarker for early axSpA detection—particularly in patients who may be HLA-B27 negative.
Augurex invites attendees to connect at EULAR 2025 to learn more about the company’s commitment to advancing autoimmune diagnostics and reducing the diagnostic delay in axSpA.
For more details about the event, visit:
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com